Topical delivery of human single-domain antibody targeting IL-33 for inhibiting mucosal inflammation

Tianlei Ying, Keke Huang, Yuqing Wu, Yu Kong, Qingyuan Xu, Yirou Zhang, Quanxiao Li, Cheng Li, Wenping Song, Xiaoyi Zhu, Zhenlin Yang, Changchang Xin, Xujiao Zhou, Yanling Wu, Jiaxu HongResearch Square 2024 · DOI

Introduction

Mucosal surfaces, including the ocular surface and the respiratory tract, represent the body's primary interface with the environment. Chronic inflammation in these regions, such as Dry Eye Disease (DED) and allergic asthma, is often driven by the release of "alarmin" cytokines like Interleukin-33 (IL-33). While monoclonal antibodies (mAbs) have revolutionized the treatment of systemic inflammatory diseases, their application in mucosal disorders is severely limited by their large molecular size (~150 kDa), which prevents efficient penetration through epithelial barriers. Consequently, patients often face invasive injections or high systemic doses to achieve therapeutic effects.

In this study, researchers developed a human single-domain antibody (UdAb), designated A12, designed to overcome these delivery hurdles. At approximately one-tenth the size of a standard IgG antibody, A12 offers a non-invasive, needle-free alternative for modulating mucosal inflammation through topical application.

Overview of A12 UdAb mechanism and topical delivery applications.

Engineering a High-Penetration Therapeutic

The researchers utilized a proprietary human UdAb library, screened via phage display, to identify A12—a high-affinity binder to human IL-33 with a dissociation constant ($K_D$) of 3.23 nM. Beyond its affinity, A12 was selected for its exceptional biophysical properties, including high solubility and structural stability. These traits are critical for topical formulations, particularly for respiratory delivery where proteins must survive the high-pressure aerosolization process of a microsprayer.

A Non-Canonical Mechanism of Action

Interestingly, A12 does not function by blocking the primary IL-33 receptor (ST2). Instead, mechanistic studies revealed that A12 interferes with the recruitment of the co-receptor IL-1RAcP. By preventing the formation of the active ternary signaling complex, A12 effectively silences the NF-κB inflammatory pathway. This "non-canonical" inhibition allows the antibody to be effective without needing to directly outcompete the high-affinity binding between IL-33 and its primary receptor.

Efficacy in Ocular and Respiratory Models

The therapeutic potential of A12 was evaluated using human IL-33 (hIL-33) transgenic mice, as the antibody is human-specific.

1. Dry Eye Disease (DED)

In ocular models, A12 demonstrated superior performance compared to Itepekimab, a clinical-stage full-sized anti-IL-33 IgG. While Itepekimab exhibited negligible penetration into the cornea, topical A12 achieved over 20-fold higher concentrations within the ocular tissue. This enhanced penetration translated to significant clinical improvement: A12-treated mice showed a dramatic reduction in Corneal Fluorescein Scores (dropping from 10.88 to 3.75 by day 14) and a restoration of goblet cell density, which is vital for maintaining a healthy tear film.

2. Allergic Asthma

For respiratory inflammation, A12 was delivered via inhalation. The UdAb maintained its integrity after aerosolization and successfully reached the deep lung tissue. In mice sensitized with ovalbumin (OVA), inhaled A12 significantly reduced overall lung inflammation, lowered serum IgE levels, and suppressed the expression of Th2-related cytokines such as IL-4, IL-5, and IL-13. The treatment also markedly reduced eosinophil infiltration in the airways.

Safety and Stability

Safety is a paramount concern for topical therapeutics. Ex vivo assays on human corneoscleral rims indicated that A12 is non-toxic, showing no signs of cell apoptosis even at concentrations as high as 100 mg/mL. Furthermore, the humanized framework of the UdAb is designed to minimize the risk of immunogenicity, though long-term studies in humans will be required to confirm the absence of anti-drug antibodies.

Conclusion

The development of A12 represents a significant step forward in the treatment of mucosal inflammatory diseases. By leveraging the small size and robustness of single-domain antibodies, this research demonstrates that potent biological therapeutics can be delivered non-invasively to the eyes and lungs. This approach not only improves patient comfort by eliminating the need for injections but also enhances therapeutic efficacy by ensuring the drug reaches the target tissue in sufficient concentrations. Future work may expand the application of A12 to other mucosal sites, such as the gastrointestinal tract for conditions like ulcerative colitis.

Summary updated

Abstract

<title>Abstract</title> Addressing mucosal inflammatory disorders in the ocular surface or respiratory system remains a formidable challenge due to limited penetration of biological therapeutics across epithelial barriers. In this study, we explored the potential of human single-domain antibodies (UdAbs) as topical therapeutics for the targeted modulation of interleukin-33 (IL-33) in two mucosal-associated inflammatory disorders. The anti-IL-33 UdAb, designated A12, demonstrated potent inhibition of the IL-33-mediated signaling pathway, despite not blocking IL-33 receptor interaction. The topical delivery of A12 achieved significantly elevated corneal concentrations <italic>in vivo</italic> compared to anti-IL-33 control IgG Itepekimab, which exhibited negligible ocular penetration. Meanwhile, A12 ameliorated the dry eye disease severity considerably by exerting anti-inflammatory effects. Furthermore, in another murine model of allergic asthma, inhaled A12 substantially reduced overall lung inflammation. Our findings revealed the capacity of UdAbs to penetrate mucosal barriers following non-invasive localized delivery, highlighting their potential as an innovative therapeutic strategy for modulating mucosal inflammation.
BibTeX
@inproceedings{ying2024topical,
  author = {Tianlei Ying and Keke Huang and Yuqing Wu and Yu Kong and Qingyuan Xu and Yirou Zhang and Quanxiao Li and Cheng Li and Wenping Song and Xiaoyi Zhu and Zhenlin Yang and Changchang Xin and Xujiao Zhou and Yanling Wu and Jiaxu Hong},
  title = {{Topical delivery of human single-domain antibody targeting IL-33 for inhibiting mucosal inflammation}},
  booktitle = {Research Square},
  year = {2024},
  doi = {10.21203/rs.3.rs-4975440/v1},
}
Figure